Loading stock data…
Indivior Pharmaceuticals, Inc. (INDV)
$34.32-0.62 (-1.77%)
Market ClosedLast close Sep 8
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Indivior Pharmaceuticals, Inc. in the Healthcare sector is trading at $34.32 with a market capitalization of $4.5B. Wall Street consensus targets $49.00 (4 analysts), implying a +42.8% move over the next 12 months. The stock is currently 20% below its 52-week high of $42.81, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 10) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $343.00M↑ | $317.00M↓ | $358.00M↑ | $314.00M↑ | $302.00M |
| Gross Profit | $293.00M↑ | $277.00M↓ | $291.00M↑ | $231.00M↓ | $250.00M |
| Operating Income | $159.00M↑ | $137.00M↑ | $83.00M↑ | $44.00M↓ | $71.00M |
| Net Income | $122.00M↑ | $89.00M↓ | $102.00M↑ | $42.00M↑ | $18.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Can...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.51B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.70
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-171.50%
Volume
Today's trading volume
1.82M
Recent News
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prompted fresh questions about valuation. See our latest analysis for Indivior Pharmaceuticals. At the current share price of $36.87, Indivior Pharmaceuticals has seen short term momentum fade, with a 1 month share price return that declined 8.85%, although the 1 year total shareholder return of...
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.